|
You are here: Home: BCU 7|2002:Hyman B Muss,
MD: Select publications
Select publications
Blum JL et al. Multicenter, Phase II study of capecitabine
in taxane-pretreated metastatic breast carcinoma patients. Cancer
2001;92(7):1759-68. Abstract
Dowsett M et al. HER-2 amplification impedes the antiproliferative
effects of hormone therapy in estrogen receptor-positive primary
breast cancer. Cancer Res 2001;61(23):8452-8. Abstract
Howell A et al. Fulvestrant, formerly ICI 182,780, is
as effective as anastrozole in postmenopausal women with advanced
breast cancer progressing after prior endocrine treatment.
J Clin Oncol 2002;20:3396-403. Abstract
Lonning PE et al. Activity of exemestane in metastatic
breast cancer after failure of nonsteroidal aromatase inhibitors:
A phase II trial. J Clin Oncol 2000;18:2234-44. Abstract
Nabholtz JM et al. Phase III trial comparing TAC (docetaxel,
doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin,
cyclophosphamide) in the adjuvant treatment of node-positive breast
cancer (BC) patients: Interim analysis of the BCIRG 001 study.
Proc ASCO 2001;Abstract
141.
Osborne CK et al. Double-blind, randomized trial comparing
the efficacy and tolerability of fulvestrant versus anastrozole
in postmenopausal women with advanced breast cancer progressing
on prior endocrine therapy: Results of a North American trial.
J Clin Oncol 2002;20:3386-95. Abstract
O’Shaughnessy JA et al. Randomized, open-label,
phase II trial of oral capecitabine (Xeloda) vs. a reference arm
of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil)
as first-line therapy for advanced/metastatic breast cancer.
Ann Oncol 2001;12(9):1247-54. Abstract
Pavlakis N, Stockler M. Bisphosphonates for breast cancer.
Cochrane Database Syst Rev 2002;(1):CD003474. Abstract
Pinto AE et al. C-erbB-2 oncoprotein overexpression identifies
a subgroup of estrogen receptorpositive (ER+) breast cancer patients
with poor prognosis. Ann Oncol 2001;12(4):525-33. Abstract
Slamon DJ et al. Use of chemotherapy plus a monoclonal
antibody against HER2 for metastatic breast cancer that overexpresses
HER2. N Engl J Med 2001;344 (11):783-92. Abstract
Talbot DC et al. Randomised, phase II trial comparing
oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced
breast cancer pretreated with anthracyclines. Br J Cancer
2002;86 (9):1367-72. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as
a single agent in first-line treatment of HER2- overexpressing metastatic
breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
|
